Yale Cancer Center Launches Center for Community Engagement and Health Equity
Yale Cancer Center has announced the launch of the Center for Community Engagement and Health Equity (CEHE). Building on the commitment of the Yale Cancer Center to patient-centered cancer care, screening, and prevention across the state of Connecticut, the new center is dedicated to ensuring cancer health equity and improving outcomes, with an emphasis on traditionally underserved neighborhoods.
Yale Cancer Center Awards for Clinical Excellence presented during annual Conclave
Debra Brandt, D.O. and Kevin Kim, M.D. were each honored with the Yale Cancer Center (YCC) Award for Clinical Excellence at YCC’s annual Conclave on Monday, January 13. The night celebrated the accomplishments of goals set for 2019 and honored faculty and staff with clinical and research prizes.
Huntington and Parker receive new appointments at Smilow Cancer Hospital
Scott Huntington, M.D., M.P.H., assistant professor of Medicine (Hematology), has been named Medical Director for the Hematology Outpatient Program at Smilow Cancer Hospital and Terri Parker, M.D., assistant Professor of Medicine (Hematology), has been appointed the inaugural Assistant Medical Director for the Smilow Cancer Hospital Care Center in North Haven, which includes multiple myeloma and benign hematology care.
Yale Scientists Breach Brain Barriers to Attack Tumors
The brain is a sort of fortress, equipped with barriers designed to keep out dangerous pathogens. But protection comes at a cost: These barriers interfere with the immune system when faced with dire threats such glioblastoma, a deadly brain tumor for which there are few effective treatments.
Sanft named Chief Patient Experience Officer at Smilow Cancer Hospital
Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale New Haven Hospital.
How to Talk to Your Kids About Your Breast Cancer Diagnosis
Almost three million children and adolescents in the United States have a parent who has or once had cancer, according to the American Academy of Child & Adolescent Psychiatry (AACAP). Among newly diagnosed adults with cancer, one in five has children under 18.
Years of excellent care give perspective on the future
Jared Rhodes’ first conversation with Dr. Erik Enquist took place nearly 16 years ago, and he is still a patient. He has since had a prostatectomy and gone through a variety of treatments to help ensure that his cancer does not come back. He’s happy to be alive and also pleased to hear that his local doctor is now also part of a larger and nationally recognized leader in medicine.
Yale Cancer Center launches Center for Community Engagement and Health Equity
Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.
Brain Scans, Aided by Artificial Intelligence, Reveal as Much About Us as Our DNA, Evan Morris Says.
“Brain scans, aided by artificial intelligence, reveal as much about us as our DNA,” Evan Morris recently wrote in an op-ed in Wired magazine. “Grappling with their ethical implications is vital to scientific integrity.”
FDA Approves Novel Drug Enfortumab Vedotin for Urothelial Cancer
The US Food and Drug Administration has granted accelerated approval to the novel agent enfortumab vedotin (PADCEV, Astellas) for the treatment of locally advanced or metastatic urothelial cancer that has progressed on chemotherapy and immunotherapy.
Backed by Yale Cancer Center Research, FDA Approves New Drug for Advanced Bladder Cancer
The U.S. Food and Drug Administration has granted accelerated approval to the drug enfortumab vedotin to treat adult patients with advanced urothelial or bladder cancer. The approval is the direct result of a multi-institutional clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers.